Alzheimer's news from FierceBiotech
NewsAlzheimer's drug results boost Elan, Wyeth
Wyeth and Elan's shares were up today as the companies announced potentially promising results from a phase II trial of bapineuzumab, an Alzheimer's treatment. The study did not attain statistical Read more...
SPOTLIGHT: Epix wins $7.5M milestone
Epix Pharmaceuticals says it's due a $7.5 million milestone payment from GSK now that it's launched a Phase IIb trial of a new therapy for Alzheimer's. Researchers say the therapy could one day be Read more...
Astellas pays $760M for Alzheimer's program
Another day, another big biotech deal. This time it's Japan's Astellas Pharma, which is paying $760 million for access to CoMentis's Alzheimer's drug. The development and commercialization agreement Read more...
Wyeth, Elan suspend Alzheimer's vaccine study
Wyeth and Elan have suspended dosing patients in a mid-stage study of the experimental Alzheimer's vaccine ACC-001 after seeing one of the patients in the study develop skin lesions. Studies of Read more...
Memory refocuses on lead programs
Memory Pharmaceuticals is retooling its operations to focus less on drug discovery research a near-term and mid- term efforts. In particular, the company is extending the preclinical research part Read more...
Glutamate a big target for drug developers
The New York Times' Alex Berenson looks at the wave of new research programs focused on the neurotransmitter Read more...
Memory's CEO steps down
Memory Pharmaceuticals' CEO Jim Sulat has announced plans to step down from the position for personal reasons. He will remain the company's part-time CFO. Taking his place for the time being is Read more...
Emerging Drug Developer: Sonexa Therapeutics
Emerging Drug Developer: Sonexa Therapeutics Sonexa Therapeutics is just the latest biotech start-up that Eckard Weber has Read more...
Start-up gains $30M in Series A funds
With human trials for an experimental Alzheimer's therapy looming, San Diego-based Sonexa Therapeutics has closed its first round of venture funds with $30 million in the bag. Domain Associates, Read more...
AstraZeneca, M.D. Anderson sign pain research deal
AstraZeneca and the University of Texas M. D. Anderson Cancer Center are teaming up to study pain caused by cancer chemotherapy, a side effect that often interferes with patients' ability to stick to Read more...
| Press ReleasesPRESS RELEASE: Biogen Idec and Neurimmune Announce $380M Alliance to Develop Treatments for Alzheimer's Diseases Biogen Idec and Neurimmune Announce $380M Alliance to Develop Treatments for Alzheimer's Diseases Cambridge, MA and Zürich, Switzerland, November 20, 2007 – Biogen Idec and Neurimmune Read more... PRESS RELEASE: Children With Alzheimer's Disease Risk Gene Show Reduced Cognitive Function Children With Alzheimer's Disease Risk Gene Show Reduced Cognitive Function Children who possess a gene known to increase the risk of Alzheimer's disease already show signs of reduced cognitive Read more... PRESS RELEASE: An Alzheimer’s Vaccine? Oklahoma City, Nov. 12, 2007 – Could a new vaccine be the key to stopping Alzheimer’s disease? A new research study from the Oklahoma Medical Research Foundation shows that immunization could Read more... PRESS RELEASE: Memory Pharmaceuticals Announces Positive Phase 2a Results for MEM 3454 in Alzheimer's Disease Memory Pharmaceuticals Announces Positive Phase 2a Results for MEM 3454 in Alzheimer's Disease MONTVALE, N.J., Nov. 2 -- Memory Pharmaceuticals Corp. today announced positive top-line data from the Read more... PRESS RELEASE: UCLA scientists pinpoint a possible physical origin of Alzheimer's disease UCLA scientists pinpoint a possible physical origin of Alzheimer's disease Discovery suggests new ways to treat disorder's cause, not just symptoms FINDINGS: For some time, scientists have blamed Read more... |
Get more Alzheimer's coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends